Transverse myelitis primary prevention
Jump to navigation
Jump to search
|
Transverse myelitis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Transverse myelitis primary prevention On the Web |
|
American Roentgen Ray Society Images of Transverse myelitis primary prevention |
|
Risk calculators and risk factors for Transverse myelitis primary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Julinka Auta Fernandes
Overview
- There are no established disease-specific measures for the primary prevention of a first episode of transverse myelitis. In particular, no medication, vaccine, screening program, diet, or dietary supplement has been shown to prevent idiopathic transverse myelitis.[1]
- Transverse myelitis is a clinical syndrome with heterogeneous immune-mediated, infectious, and other causes rather than a single disease with one preventable exposure. Measures that prevent a particular infection or manage another underlying condition may provide general health benefits, but they have not been proven to prevent transverse myelitis itself.[1]
| Primary-prevention principle: An asymptomatic person should not receive disease-specific testing, medication, supplements, or vaccine restrictions solely in an attempt to prevent transverse myelitis. Prevention of another attack after an initial myelitis episode is secondary prevention and is outside the scope of this page. |
Primary Prevention
Disease-specific prevention
| Proposed approach | Current recommendation | Evidence boundary |
|---|---|---|
| Disease-specific vaccine | No vaccine is available to prevent transverse myelitis. | Vaccines may prevent individual infectious diseases, but none is licensed or recommended specifically to prevent transverse myelitis.[2][3] |
| Preventive medication or immunotherapy | No prophylactic medication or immune-directed treatment is recommended for an otherwise unaffected person solely to prevent transverse myelitis. | Treatment of an established myelitis event and prevention of recurrence after an initial event are not primary-prevention interventions.[1] |
| Screening-led prophylaxis | No population-based laboratory, antibody, genetic, or imaging screening program is recommended to identify asymptomatic people for transverse-myelitis prophylaxis. | Diagnostic and recurrence-risk testing is performed after compatible neurological symptoms or a myelitis event and does not constitute primary prevention.[1] |
| Diet, vitamins, or supplements | No special diet, vitamin dose, herbal product, or other supplement is recommended specifically to prevent transverse myelitis. | Nutritional deficiencies should be assessed and treated for their usual clinical indications, but this should not be presented as proven prevention of inflammatory transverse myelitis.[1] |
| General infection prevention | Follow routine public-health recommendations appropriate to age, medical risk, occupation, travel, and local epidemiology. | These measures reduce specific infections and provide broad health benefits; their direct effect on the incidence of transverse myelitis has not been established.[2][3] |
Vaccination guidance
- Vaccination should follow the current national schedule and established product-specific indications, contraindications, and precautions. Current guidance from the United States Centers for Disease Control and Prevention and the European Centre for Disease Prevention and Control contains no separate vaccination schedule for preventing transverse myelitis.[2][3]
- Routine vaccination should not be withheld from an otherwise eligible, asymptomatic person solely as an unproven strategy to prevent transverse myelitis. Before each vaccine dose, clinicians should apply the standard contraindications and precautions for that specific product and the patient's current clinical condition.[4]
- Case reports or a temporal association alone should not be converted into a general transverse-myelitis vaccine restriction; the American professional-society review notes that causation between immunization and acute transverse myelitis has not been established.[1]
Clinical counseling
- Clinicians should explain that the absence of a proven primary-prevention strategy does not mean routine preventive care is unnecessary. Patients should continue recommended immunization and ordinary infection-prevention practices for their established benefits.
- Claims that a particular diet, supplement, detoxification regimen, prophylactic antibiotic or antiviral drug, or immune-directed treatment prevents transverse myelitis should not be made without disease-specific evidence.
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 Hartman KC, Helm D. Transverse Myelitis. American Academy of Physical Medicine and Rehabilitation. Physical Medicine and Rehabilitation (PM&R) KnowledgeNow. Updated November 21, 2024. Accessed October 9, 2026.
- ↑ 2.0 2.1 2.2 Centers for Disease Control and Prevention (CDC). Introduction to Immunization Best Practice. Updated June 13, 2024. Accessed October 9, 2026.
- ↑ 3.0 3.1 3.2 European Centre for Disease Prevention and Control (ECDC). Vaccine schedules in all countries in the European Union and European Economic Area. 2026. Accessed October 9, 2026.
- ↑ Centers for Disease Control and Prevention (CDC). Contraindications and Precautions. Updated July 25, 2024. Accessed October 9, 2026.